American Association for Cancer Research
crc-22-0434-s10.png (40.79 kB)

Supplementary Figure 10 from Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma

Download (40.79 kB)
posted on 2023-07-06, 14:20 authored by Michal Nisnboym, Sarah R. Vincze, Zujian Xiong, Chaim T. Sneiderman, Rebecca A. Raphael, Bo Li, Ambika P. Jaswal, ReidAnn E. Sever, Kathryn E. Day, Joseph D. LaToche, Lesley M. Foley, Hanieh Karimi, T. Kevin Hitchens, Sameer Agnihotri, Baoli Hu, Dhivyaa Rajasundaram, Carolyn J. Anderson, Deborah T. Blumenthal, Thomas M. Pearce, Shikhar Uttam, Jessie R. Nedrow, Ashok Panigrahy, Ian F. Pollack, Frank S. Lieberman, Jan Drappatz, Itay Raphael, Wilson B. Edwards, Gary Kohanbash

MRI analysis of tumor volume before and after treatment.


HHS | NIH | National Cancer Institute (NCI)

HHS | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB)



Immunotherapy may hold promise for the treatment of some patients with GBM. There is a need to assess therapy responsiveness to allow the continuation of effective treatment in responders and to avoid ineffective treatment with potential adverse effects in the nonresponders. We demonstrate that noninvasive PET/CT imaging of CD69 may allow early detection of immunotherapy responsiveness in patients with GBM.